NCT01444716View on ClinicalTrials.gov

Ofatumumab as Front-Line Therapy in Treating Elderly Participants With Chronic Lymphocytic Leukemia

PHASE2CompletedINTERVENTIONAL
Enrollment

34

Participants

Timeline

Start Date

December 15, 2011

Primary Completion Date

June 11, 2020

Study Completion Date

June 11, 2020

Conditions
Chronic Lymphocytic Leukemia
Interventions
BIOLOGICAL

Ofatumumab

Given IV

Trial Locations (1)

77030

M D Anderson Cancer Center, Houston

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

M.D. Anderson Cancer Center

OTHER

NCT01444716 - Ofatumumab as Front-Line Therapy in Treating Elderly Participants With Chronic Lymphocytic Leukemia | Biotech Hunter | Biotech Hunter